{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T11:32:05Z","timestamp":1792150325985,"version":"4.4.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.clinthera.2021.11.008","type":"journal-article","created":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T00:57:05Z","timestamp":1640912225000},"page":"67-80.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Population Pharmacokinetic and Pharmacodynamic Analysis of Polmacoxib in Healthy Volunteers and Patients With Osteoarthritis"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1424-1123","authenticated-orcid":false,"given":"Yong-Soon","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7399-5879","authenticated-orcid":false,"given":"Kyun-Seop","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Chan","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joong Myung","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1420-8200","authenticated-orcid":false,"given":"Hyeong-Seok","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2021.11.008_bib0001","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1007\/s10067-006-0240-3","article-title":"The burden of musculoskeletal disease\u2013a global perspective","volume":"25","author":"Brooks","year":"2006","journal-title":"Clinical rheumatology"},{"key":"10.1016\/j.clinthera.2021.11.008_bib0002","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.joca.2011.08.009","article-title":"The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review","volume":"19","author":"Pereira","year":"2011","journal-title":"Osteoarthritis and cartilage"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2021.11.008_bib0003","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1097\/01.blo.0000143938.30681.9d","article-title":"The impact of osteoarthritis: implications for research","volume":"427","author":"Buckwalter","year":"2004","journal-title":"Clinical orthopaedics and related research"},{"key":"10.1016\/j.clinthera.2021.11.008_bib0004","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1093\/rheumatology\/kei049","article-title":"The economic burden of disabling hip and knee osteoarthritis (OA) from the perspective of individuals living with this condition","volume":"44","author":"Gupta","year":"2005","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.clinthera.2021.11.008_bib0005","first-page":"49","article-title":"Osteoarthritis: diagnosis and treatment","volume":"85","author":"Sinusas","year":"2012","journal-title":"American family physician"},{"key":"10.1016\/j.clinthera.2021.11.008_bib0006","first-page":"841","article-title":"Osteoarthritis: diagnosis and therapeutic considerations","volume":"65","author":"Hinton","year":"2002","journal-title":"American family physician"},{"key":"10.1016\/j.clinthera.2021.11.008_bib0007","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.21596","article-title":"American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee","volume":"64","author":"Hochberg","year":"2012","journal-title":"Arthritis care & research"},{"key":"10.1016\/j.clinthera.2021.11.008_bib0008","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/rheumatology\/37.5.546","article-title":"The clinical management of rheumatoid arthritis and osteoarthritis: strategies for improving clinical effectiveness","volume":"37","author":"Scott","year":"1998","journal-title":"British journal of rheumatology"},{"key":"10.1016\/j.clinthera.2021.11.008_bib0009","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/archinte.158.10.1108","article-title":"NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics","volume":"158","author":"Heerdink","year":"1998","journal-title":"Archives of internal medicine"},{"key":"10.1016\/j.clinthera.2021.11.008_bib0010","first-page":"1177","article-title":"Approach to managing musculoskeletal pain: acetaminophen, cyclooxygenase-2 inhibitors, or traditional NSAIDs?","volume":"53","author":"Hunt","year":"2007","journal-title":"Canadian family physician Medecin de famille canadien"},{"key":"10.1016\/j.clinthera.2021.11.008_bib0011","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0140-6736(91)90744-A","article-title":"Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Catalan Countries Study on Upper Gastrointestinal Bleeding","volume":"337","author":"Laporte","year":"1991","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.clinthera.2021.11.008_bib0012","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1160\/TH06-08-0444","article-title":"The pharmacology of selective inhibition of COX-2","volume":"96","author":"Grosser","year":"2006","journal-title":"Thrombosis and haemostasis"},{"key":"10.1016\/j.clinthera.2021.11.008_bib0013","doi-asserted-by":"crossref","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2021.11.008_bib0014","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1159\/000086459","article-title":"Selective COX-2 inhibitors and risk of myocardial infarction","volume":"42","author":"Krotz","year":"2005","journal-title":"Journal of vascular research"},{"key":"10.1016\/j.clinthera.2021.11.008_bib0015","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.tips.2007.01.003","article-title":"Balancing prostanoid activity in the human vascular system","volume":"28","author":"Flavahan","year":"2007","journal-title":"Trends in pharmacological sciences"},{"key":"10.1016\/j.clinthera.2021.11.008_bib0016","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.lfs.2010.10.017","article-title":"Inducible COX-2 dominates over COX-1 in prostacyclin biosynthesis: mechanisms of COX-2 inhibitor risk to heart disease","volume":"88","author":"Ruan","year":"2011","journal-title":"Life sciences"},{"key":"10.1016\/j.clinthera.2021.11.008_bib0017","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1471-2261-12-93","article-title":"Comparative effects of non-steroidal anti-inflammatory drugs (NSAIDs) on blood pressure in patients with hypertension","volume":"12","author":"Aljadhey","year":"2012","journal-title":"BMC cardiovascular disorders"},{"key":"10.1016\/j.clinthera.2021.11.008_bib0018","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/archinte.165.5.ioi50013","article-title":"Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure","volume":"165","author":"Aw","year":"2005","journal-title":"Archives of internal medicine"},{"key":"10.1016\/j.clinthera.2021.11.008_bib0019","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/clpt.2012.3","article-title":"Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649","volume":"91","author":"Skarke","year":"2012","journal-title":"Clinical pharmacology and therapeutics"},{"key":"10.1016\/j.clinthera.2021.11.008_bib0020","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/cpdd.47","article-title":"GCG100649, A Novel Cyclooxygenase-2 Inhibitor, Exhibits a Drug Disposition Profile in Healthy Volunteers Compatible With High Affinity to Carbonic Anhydrase-I\/II: Preliminary Dose-Exposure Relationships to Define Clinical Development Strategies","volume":"2","author":"Hirankarn","year":"2013","journal-title":"Clinical pharmacology in drug development"},{"key":"10.1016\/j.clinthera.2021.11.008_bib0021","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.clinthera.2014.07.007","article-title":"Pharmacokinetic, pharmacodynamic, and safety\/tolerability profiles of CG100649, a novel COX-2 inhibitor: results of a phase i, randomized, multiple-dose study in healthy Korean men and women","volume":"37","author":"Kim","year":"2015","journal-title":"Clinical therapeutics"},{"key":"10.1016\/j.clinthera.2021.11.008_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2016.07.114","article-title":"Structural insight into the inhibition of carbonic anhydrase by the COX-2-selective inhibitor polmacoxib (CG100649)","volume":"478","author":"Kim","year":"2016","journal-title":"Biochemical and biophysical research communications"},{"key":"10.1016\/j.clinthera.2021.11.008_bib0023","series-title":"Biochemistry","article-title":"Carbonic anhydrase and heavy metals","author":"Lionetto","year":"2012"},{"key":"10.1016\/j.clinthera.2021.11.008_bib0024","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ica.2015.12.031","article-title":"Metal complexes of benzimidazole derived sulfonamide: Synthesis, molecular structures and antimicrobial activity","volume":"443","author":"Ashraf","year":"2016","journal-title":"Inorganica Chimica Acta"},{"key":"10.1016\/j.clinthera.2021.11.008_bib0025","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1567-5769(01)00204-1","article-title":"Cyclooxygenases and prostaglandins: shaping up the immune response","volume":"2","author":"Rocca","year":"2002","journal-title":"International immunopharmacology"},{"key":"10.1016\/j.clinthera.2021.11.008_bib0026","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0163-7258(01)00165-6","article-title":"Alteration of drug biotransformation and elimination during infection and inflammation","volume":"92","author":"Renton","year":"2001","journal-title":"Pharmacology & therapeutics"},{"key":"10.1016\/j.clinthera.2021.11.008_bib0027","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1517\/17425255.1.4.629","article-title":"Regulation of drug metabolism and disposition during inflammation and infection","volume":"1","author":"Renton","year":"2005","journal-title":"Expert opinion on drug metabolism & toxicology"},{"key":"10.1016\/j.clinthera.2021.11.008_bib0028","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"British journal of clinical pharmacology"},{"key":"10.1016\/j.clinthera.2021.11.008_bib0029","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2174\/138920011796504527","article-title":"Age-related changes in pharmacokinetics","volume":"12","author":"Shi","year":"2011","journal-title":"Current drug metabolism"},{"key":"10.1016\/j.clinthera.2021.11.008_bib0030","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.clinthera.2013.12.004","article-title":"Effects of ketoconazole on the pharmacokinetic properties of CG100649, a novel NSAID: a randomized, open-label crossover study in healthy Korean male volunteers","volume":"36","author":"Youn Choi","year":"2014","journal-title":"Clinical therapeutics"},{"key":"10.1016\/j.clinthera.2021.11.008_bib0031","doi-asserted-by":"crossref","first-page":"12872","DOI":"10.4238\/2015.October.21.7","article-title":"Differential expression of COX-2 in osteoarthritis and rheumatoid arthritis","volume":"14","author":"Fan","year":"2015","journal-title":"Genetics and molecular research"},{"key":"10.1016\/j.clinthera.2021.11.008_bib0032","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/rheumatology\/37.7.773","article-title":"Detection of COX-1 and COX-2 isoforms in synovial fluid cells from inflammatory joint diseases","volume":"37","author":"Iniguez","year":"1998","journal-title":"British journal of rheumatology"},{"key":"10.1016\/j.clinthera.2021.11.008_bib0033","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/ar3437","article-title":"Celecoxib: considerations regarding its potential disease-modifying properties in osteoarthritis","volume":"13","author":"Zweers","year":"2011","journal-title":"Arthritis research & therapy"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182100463X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182100463X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:56:08Z","timestamp":1758963368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929182100463X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S014929182100463X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.11.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population Pharmacokinetic and Pharmacodynamic Analysis of Polmacoxib in Healthy Volunteers and Patients With Osteoarthritis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}